Business · Companies · 1 hr ago
Argent BioPharma licenses four cannabis genotypes to Thai partner
Argent BioPharma has licensed four cannabis genotypes to Thai Phytomed International for commercial development worldwide.
The exclusive licence lasts 10 years, with an option to renew for another 10 years.
Argent will keep ownership of the genetics and related intellectual property, and can still use them for its own pharmaceutical research.
Argent will receive 15% of commercialisation profits, calculated quarterly.
Thai Phytomed will pay for development and handle the regulatory and operational approvals needed in each market.
The deal lets Argent focus its resources on pharmaceutical development while seeking income from older assets.
Argent may end the licence if no licensed product is sold within 24 months of delivery of the genetic material.
Argent BioPharma signed a 10-year exclusive global licensing agreement with Thai Phytomed International for four proprietary cannabis genotypes.
Argent retains ownership of the genetics and associated intellectual property.
Thai Phytomed will fund commercial development and receive exclusive commercialisation rights within the agreement’s scope.
Argent will receive 15% of profits generated from commercialisation, calculated quarterly.
The agreement supports Argent’s plan to monetise non-core cannabis assets and focus resources on pharmaceutical development.
- Who
- Argent BioPharma and Thai Phytomed International.
- What
- They signed an exclusive global licence covering the commercial development of four cannabis genotypes. Argent retains ownership and will receive 15% of commercialisation profits.
- When
- The agreement was reported on 27 October 2026. Its initial term is 10 years.
- Where
- Worldwide.
- Why
- Argent said the deal supports its strategy to monetise non-core assets and focus resources on pharmaceutical development.
This story does not have two clearly opposing sides.
RGT licensed CannEpil to NYSE-listed Splash Beverage Group.
Stockhead reported Argent’s 10-year global licensing agreement with Thai Phytomed International.
- Licensed genotypes
- MXC-THC-10/3; MXC-THC-81/5; MXC-THC-40/3; MXC-THC-40/2
- Initial term
- 10 years, with an option to renew for a further 10 years
- Royalty
- 15% of profits generated from commercialisation, calculated quarterly
- Commercial partner
- Thai Phytomed International
- Termination condition
- Argent may terminate if no commercial sale occurs within 24 months after delivery of the licensed genetic material.
What people are saying
These genetics represent intellectual property developed within the group over many years.